NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 356 filers reported holding NEKTAR THERAPEUTICS in Q1 2019. The put-call ratio across all filers is 1.71 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2021 | $1,497,000 | -11.2% | 110,820 | +18.1% | 0.01% | -7.7% |
Q3 2021 | $1,685,000 | -16.0% | 93,800 | -19.7% | 0.01% | -13.3% |
Q2 2021 | $2,006,000 | -77.5% | 116,871 | -73.8% | 0.02% | -77.6% |
Q1 2021 | $8,918,000 | +410.2% | 445,922 | +333.6% | 0.07% | +415.4% |
Q4 2020 | $1,748,000 | -87.3% | 102,831 | -87.6% | 0.01% | -89.2% |
Q3 2020 | $13,774,000 | -33.6% | 830,262 | -7.4% | 0.12% | -34.8% |
Q2 2020 | $20,755,000 | +3.2% | 896,172 | -20.4% | 0.18% | -18.6% |
Q1 2020 | $20,103,000 | +39.8% | 1,126,206 | +69.0% | 0.23% | +113.2% |
Q4 2019 | $14,384,000 | -0.5% | 666,400 | -16.1% | 0.11% | -6.2% |
Q3 2019 | $14,461,000 | -52.9% | 793,906 | -8.0% | 0.11% | -51.3% |
Q2 2019 | $30,710,000 | +10.3% | 863,129 | +4.2% | 0.23% | +17.2% |
Q1 2019 | $27,833,000 | +6.5% | 828,350 | +4.1% | 0.20% | -6.2% |
Q4 2018 | $26,144,000 | -67.0% | 795,389 | -38.7% | 0.21% | -58.6% |
Q3 2018 | $79,144,000 | +48.4% | 1,298,286 | +18.8% | 0.51% | +34.9% |
Q2 2018 | $53,342,000 | -25.7% | 1,092,395 | +61.6% | 0.38% | -27.7% |
Q1 2018 | $71,838,000 | – | 676,058 | – | 0.52% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Ally Bridge Group (NY) LLC | 432,952 | $1,385,000 | 0.91% |
GREAT POINT PARTNERS LLC | 447,820 | $1,433,000 | 0.34% |
Birchview Capital, LP | 128,000 | $410,000 | 0.29% |
Edgestream Partners, L.P. | 1,047,636 | $3,352,000 | 0.26% |
Rhenman & Partners Asset Management AB | 550,000 | $2,068,000 | 0.22% |
CM Management, LLC | 50,000 | $160,000 | 0.18% |
TANG CAPITAL MANAGEMENT LLC | 430,037 | $1,376,000 | 0.17% |
PDT Partners, LLC | 307,953 | $985,000 | 0.15% |
Virtus ETF Advisers LLC | 72,018 | $230,000 | 0.09% |
ALGERT GLOBAL LLC | 476,412 | $1,525,000 | 0.09% |